UK Prime Minister Theresa May has called for the United Kingdom to remain a member of the European Medicines Agency (EMA), but the European Council says that "The Union will preserve its autonomy as regards its decision-making, which excludes participation of the United Kingdom as a third-country to EU Institutions."
Earlier this month, UK Prime Minister Theresa May gave a speech discussing the future of the United Kingdom’s relationship with the European Union. In her speech, May called for the United Kingdom to remain a member of the European Medicines Agency (EMA), which is currently being relocated from London, United Kingdom, to Amsterdam, Netherlands in preparation for Brexit.
In response, the General Secretariat of the Council sent a note on its draft guidelines to the Permanent Representatives Committee.
While the Council’s note reiterated the European Union’s determination to have “as close as possible a partnership” with the United Kingdom in the future, one that would cover trade and economic cooperation as well as other areas, such as security, defense, and foreign policy, it said that “The European Council further reiterates that the Union will preserve its autonomy as regards its decision-making, which excludes participation of the United Kingdom as a third-country to EU Institutions, agencies or bodies. The role of the Court of Justice of the European Union will also be fully respected.” This assertion stands in contrast to May’s statement that the UK Parliament would “would remain ultimately sovereign” with respect to adopting or not adopting the EMA’s rules and regulations.
Furthermore, the European Council noted that it must “…take into account the repeatedly stated positions of the UK, which limit the depth of such a future partnership. Being outside the Customs Union and the Single Market will inevitably lead to frictions."
Importantly, the European Commission’s draft guidelines also noted the following:
According to the Financial Times, the United Kingdom’s Medicines and Healthcare Products Regulatory Agency is currently leading 35% of the EMA’s medicines safety monitoring programs, and about 40% of the evaluation of highly complex therapies.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.